Subscribe

Poly Medicure Limited (POLYMED.NS)

INR1,715.60 +51.20 (+3.08%)
IN NSE Healthcare Medical - Instruments & Supplies
Address 232B Okhla Industrial Estate 110020
New Delhi, IN
CEO Himanshu Baid
IPO 2011-12-07
ISIN INE205C01021

Explore sections of this company profile

Also trades on Bombay Stock Exchange · POLYMED.BO (INR) National Stock Exchange of India · POLYMED.NS (INR)
Description

Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR1,715.60 +51.20 (+3.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
174.2K
Beta
0.06
Float Shares
33.56M
Free Float %
33.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-6.94% -1.72% +1.81% +14.39% -24.20% -18.83% -40.87% +47.64% +42.28% +725.10% +4,228.92%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1,715.60
Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 3 0
Hold 1 0
Sell 0 0
Strong Sell 1 0
Quality scores
Altman Z-Score
12.61
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Instruments & Supplies: +7.9%
    +12.3% Q1'26: +21.3% (vs Q1'25)
  • EPS growth Medical - Instruments & Supplies: +16.3%
    -6.9% Q1'26: -26.8% (vs Q1'25)
  • FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%
    +2.8% Q1'26: -12.3% (vs Q1'25)
  • EBIT margin Medical - Instruments & Supplies: +13.5%
    +17.4% Q1'26: +13.5% (vs Q1'25)
  • ROIC Medical - Instruments & Supplies: +6.0%
    +9.3% Q1'26: +8.4% (vs Q1'25)
  • Share dilution Medical - Instruments & Supplies: +0.1%
    +2.2% Q1'26: -1.4% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×
    0.80× Q1'26: 0.80× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.13) × ERP
WACC = 98% × Ke + 2% × Kd (5.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 1,715.60
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2013
actual
Mar 2015
actual
Mar 2016
actual
Mar 2017
actual
Mar 2018
actual
Mar 2019
actual
Mar 2020
actual
Mar 2021
actual
Mar 2022
actual
Mar 2023
actual
Mar 2024
actual
Mar 2025
actual
Mar 2026
6 Rev. Ana.
6 EPS Ana.
Mar 2027
6 Rev. Ana.
5 EPS Ana.
Mar 2028
6 Rev. Ana.
5 EPS Ana.
Revenue
2.60B
est: 2.49B (+4.5%)
3.90B
est: 3.76B (+3.9%)
4.12B
est: 3.90B (+5.7%)
4.55B
est: 4.50B (+1.0%)
5.20B
est: 5.01B (+3.8%)
6.11B
est: 5.93B (+2.9%)
6.87B
est: 6.72B (+2.3%)
7.86B
est: 7.87B (-0.1%)
9.23B
est: 9.12B (+1.2%)
11.15B
est: 11.11B (+0.3%)
13.76B
est: 13.64B (+0.9%)
16.70B
est: 16.90B (-1.2%)
18.92B
18.39B – 19.34B
+12.0% YoY
22.42B
21.32B – 23.59B
+18.5% YoY
26.70B
24.84B – 29.33B
+19.1% YoY
EBITDA
689.87M
est: 631.63M (+9.2%)
841.59M
est: 954.58M (-11.8%)
857.76M
est: 976.56M (-12.2%)
922.01M
est: 1.13B (-18.3%)
1.20B
est: 1.26B (-4.8%)
1.30B
est: 1.48B (-12.2%)
1.63B
est: 1.64B (-0.9%)
2.13B
est: 1.97B (+7.8%)
2.12B
est: 1.96B (+8.2%)
2.68B
est: 2.78B (-3.8%)
3.58B
est: 3.47B (+3.2%)
4.52B
est: 4.29B (+5.3%)
4.81B
4.67B – 4.92B
+12.0% YoY
5.70B
5.42B – 5.99B
+18.5% YoY
6.79B
6.31B – 7.45B
+19.1% YoY
EBIT
562.89M
est: 504.00M (+11.7%)
653.52M
est: 761.70M (-14.2%)
647.47M
est: 779.24M (-16.9%)
690.91M
est: 900.07M (-23.2%)
911.62M
est: 854.53M (+6.7%)
936.95M
est: 1.19B (-21.0%)
1.24B
est: 1.34B (-7.7%)
1.67B
est: 1.57B (+6.1%)
1.60B
est: 1.61B (-0.9%)
2.13B
est: 1.99B (+7.1%)
2.96B
est: 2.77B (+7.1%)
3.72B
est: 3.43B (+8.5%)
3.84B
3.73B – 3.92B
+12.0% YoY
4.54B
4.32B – 4.78B
+18.5% YoY
5.41B
5.04B – 5.95B
+19.1% YoY
Net Income
242.30M
est: 193.60M (+25.2%)
623.23M
est: 689.75M (-9.6%)
482.68M
est: 686.43M (-29.7%)
551.25M
est: 314.49M (+75.3%)
705.94M
est: 701.03M (+0.7%)
653.99M
est: 712.72M (-8.2%)
958.78M
est: 1.06B (-9.2%)
1.36B
est: 1.46B (-7.0%)
1.47B
est: 1.25B (+17.2%)
1.79B
est: 1.91B (-6.1%)
2.58B
est: 2.64B (-2.2%)
3.39B
est: 3.28B (+3.1%)
3.43B
3.22B – 3.55B
+4.4% YoY
3.93B
3.58B – 4.07B
+14.5% YoY
4.83B
4.23B – 5.29B
+23.0% YoY
SGA
589.92M
est: 457.48M (+28.9%)
686.62M
est: 691.40M (-0.7%)
791.25M
est: 707.32M (+11.9%)
930.87M
est: 817.00M (+13.9%)
1.04B
est: 909.31M (+13.9%)
1.22B
est: 1.08B (+13.8%)
1.43B
est: 1.22B (+17.4%)
1.45B
est: 1.43B (+1.4%)
1.67B
est: 2.86B (-41.6%)
2.08B
est: 3.31B (-37.3%)
2.52B
est: 2.51B (+0.2%)
3.11B
est: 3.11B (-0.1%)
3.48B
3.38B – 3.56B
+12.0% YoY
4.13B
3.92B – 4.34B
+18.5% YoY
4.91B
4.57B – 5.40B
+19.1% YoY
EPS
2.75
est: 1.95 (+41.0%)
7.07
est: 6.95 (+1.7%)
5.47
est: 7.05 (-22.4%)
6.25
est: 3.23 (+93.5%)
8.00
est: 7.20 (+11.1%)
7.41
est: 7.32 (+1.2%)
10.86
est: 10.84 (+0.2%)
15.25
est: 15.00 (+1.7%)
15.28
est: 14.65 (+4.3%)
18.69
est: 19.60 (-4.6%)
26.92
est: 26.60 (+1.2%)
34.13
est: 33.10 (+3.1%)
34.56
32.40 – 35.74
+4.4% YoY
39.56
36.10 – 41.00
+14.5% YoY
48.66
42.60 – 53.30
+23.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-26 B 3/5 1/5 4/5 5/5 3/5 1/5 2/5
2026-05-25 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
457.24M
OE per share TTM
4.50
Owner's Yield
0.31%
Maintenance CapEx ratio
155.19%
Maint CapEx / Avg PPE
62.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 16 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Vanguard FTSE All-World ex-US Small-Cap ETF VSS 0.01% 1.75M 0.06%
2 Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO 0.00% 129.1K 0.26%
3 Vanguard FTSE Emerging Markets Shares ETF VGE.AX 0.00% 57.2K 0.48%
4 Vanguard FTSE Emerging Markets ETF VWO 0.00% 6.37M 0.06%
5 Vanguard ESG International Stock ETF VSGX 0.00% 86.0K 0.10%
6 Vanguard Total International Stock ETF VXUS 0.00% 6.78M 0.05%
7 Vanguard Total World Stock ETF VT 0.00% 401.0K 0.06%
8 Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO 0.00% 10.2K 0.22%
9 Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L 0.00% 5.4K 0.24%
10 Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L 0.00% 5.4K 0.24%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
518.7K
Shares Outstanding
101.36M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Himanshu Baid Chief Executive Officer, MD & Director 214M male
Rishi Baid Joint MD & Executive Director 209M male
Vishal Baid Executive Director & Senior Vice President of Corporate Sales & Marketing 20M male
Jugal Kishore Baid Founder & Non Executive Director 2M male
Pankaj Kumar Gupta President of R&D & Additional Executive Director male
Rahul Gautam President of Strategy & Corporate Development male
Naresh Vijayvergiya Chief Financial Officer male
K. Rastogi Assistant Vice President of Finance & Accounts male
Lokender Kumar Senior General Manager & HR male
Avinash Chandra Company Secretary & Compliance Officer male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits